key: cord-1048759-nhlct2ax
authors: Brown, Stacey-Ann Whittaker; Iancu-Rubin, Camelia; Aboelela, Adam; Abrahams, Alex; Burke, Elizabeth; Drummond, Tiffany; Grossman, Fred; Itescu, Silviu; Lagdameo, Jonathan; Lin, Jung-Yi; Mark, Alexis; Levine, John E.; Osman, Keren
title: Mesenchymal Stromal Cell Therapy for Acute Respiratory Distress Syndrome due to COVID-19
date: 2022-04-11
journal: Cytotherapy
DOI: 10.1016/j.jcyt.2022.03.006
sha: 14dcdee3cf0eb57765782c0854ca890b046a7d7e
doc_id: 1048759
cord_uid: nhlct2ax

The acute respiratory distress syndrome (ARDS) resulting from coronavirus disease 2019 (COVID-19) is associated with a massive release of inflammatory cytokines and high mortality. Mesenchymal stromal cells (MSCs) have anti-inflammatory properties and have shown activity in treating acute lung injury. Here, we report a case series of 11 patients with COVID-19-associated ARDS (CARDS), requiring mechanical ventilation, who were treated with remestemcel-L, an allogeneic MSC product, under individual patient emergency investigational new drug (eIND) applications. Patients were eligible if they were mechanically ventilated for less than 72 hours prior to the first infusion. Patients with pre-existing lung disease requiring supplemental oxygen or severe liver or kidney injury were excluded. Each patient received two infusions of remestemcel-L at a dose of 2 million cells/kg/infusion, 48-120 hours apart. Remestemcel-L infusions were well-tolerated in all eleven patients. At the end of the 28-days follow-up period 10 patients (91%, 95% confidence interval [CI]; 59-100%) were extubated, 9 patients (82%, 95% CI; 48-97%) remained liberated from mechanical ventilation and were discharged from the ICU and two (18%, 95 CI%; 2-52%) died. The median time to extubation was ten days. 8 patients (73%, 95% CI; 34-100%) were discharged from the hospital. C-reactive protein levels significantly declined within five days of MSC infusion. In summary, we demonstrate that in this case series remestemcel-L infusions to treat moderate to severe CARDS were safe, well-tolerated and resulted in improved clinical outcome.

The 2019 coronavirus SARS-CoV-2 and associated disease (COVID-19) is a global public health emergency with over 69 million confirmed cases and 860,386 deaths in the United States [1] .

While most affected patients recover from COVID-19 infection without sequelae, early reports in the early days of the pandemic demonstrate that up to 42% of hospitalized patients developed acute respiratory distress syndrome (ARDS) [2] [3] [4] [5] . The COVID-19 patient with ARDS (CARDS) has unique features including relatively high lung compliance in the early phase, however there may be progression to a more typical presentation of ARDS with poorly compliant lung, worsening alveolar infiltrates and high mortality [6] . In a retrospective cohort of 201 Chinese patients with COVID-19, the mortality was 66% among those who received mechanical ventilation [3] , however more recent reports suggest that mortality rate may vary [7] . There are no currently approved therapies for CARDS; current standard of care includes lung protective ventilation and conservative fluid management [8] . In the early phase of CARDS, targeting a lower positive end-expiratory pressure (PEEP) and reducing rigorous spontaneous inspiratory efforts may lower the sheer forces on the hyperpermeable microvasculature [6] . There is an urgent need to improve the morbidity and mortality for patients and to reduce ventilator days and intensive care unit (ICU) length of stay given the burden of this pandemic on healthcare resources.

Recent publications have identified the "cytokine storm", a massive inflammatory cytokine release, as an underlying insult leading to lung injury in COVID-19 [9] . We reasoned that infusions of allogeneic mesenchymal stromal cells (MSCs), which exert broad, antiinflammatory effects may be of benefit in patients with this condition characterized by pathological immune activation and inflammation. MSCs suppress T-cell proliferation in response to allo-antigenic and mitogenic challenge, decrease the secretion of inflammatory cytokines such as interferon-gamma (IFNγ) and tumor-necrosis factor-alpha (TNFα) and increase the secretion of anti-inflammatory cytokines (e.g, interleukin-4 and -10) by multiple immune cell subsets [10] [11] [12] . MSCs are also characterized by a hypo-immunogeneic phenotype which decreases rejection of these allogeneic cells by the host.

The promising efficacy of MSC infusions has been demonstrated in clinical trials of steroidrefractory acute graft-vs-host disease (SR aGVHD) [13] [14] [15] and in pre-clinical models of acute lung injury [10, 16] . MSCs have demonstrated safety in phase 1/2a trials of ARDS [17, 18] . A small study in China reported 7 patients with COVID-19 pneumonia who were not mechanically ventilated recovered quickly with improved inflammatory markers after being treated with MSCs [19] . In this report, we used remestemcel-L, an investigational , allogeneic, bone marrowderived, off-the-shelf cryopreserved MSC product candidate to treat patients with moderate to severe CARDS requiring mechanical ventilation.

This report is a series of consecutive cases of patients with CARDS treated at a single academic center between March-April, 2020. Patients were observed at a minimum until death or ICU discharge, whichever came first. Each patient was treated under individual emergency Investigational New Drug applications (eINDs) approved by the United States Food and Drug Administration (FDA) and the Institutional Review Board of the Icahn School of Medicine at Mount Sinai. Informed consent was obtained from patients or their legally authorized representative. CARDS was defined according to the modified Berlin criteria as the acute onset of hypoxemic respiratory failure manifested by bilateral opacities on chest imaging not fully explained by pleural effusions, lobar collapse or lung nodules [20] . Furthermore, the clinical deterioration could not be fully explained by cardiac failure or fluid overload. The degree of oxygen impairment was characterized by the ratio of the partial pressure of oxygen in arterial blood to the fraction of inspired supplemental oxygen (P:F ratio) on a minimum PEEP of greater than or equal to five cm H 2 0. Moderate ARDS was defined as P:F ratio between 101-200 mmHg and severe ARDS as ratio ≤100 mmHg.

Patients were eligible if they had SARs-CoV-2 infection confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) assay on nasopharyngeal sampling with moderate to severe ARDS. The severity of ARDS was determined by the lowest P:F ratio within the first 24 hours of intubation.

Additional inclusion criteria were invasive mechanical ventilation for less than 72 hours prior to infusion, C-reactive protein level (a non-specific marker of inflammation) ≥ 4.0 mg/dL (or 40mg/L), baseline Acute Physiology and Chronic Health Evaluation (APACHE) II Score (a measure of ICU mortality risk score, assessed by the worst physiologic parameters within 24 hours of ICU admission) [21] ≥5 and absence of severe liver injury (alanine and aspartate aminotransferases less than 5 times the upper limit of normal) or renal dysfunction (serum creatinine<2.0 mg/dL or creatinine clearance ≥30 milliters per minute; Supplemental Table S1 ).

Patients were excluded from participation if they were currently receiving extracorporeal membrane oxygenation (ECMO), had known hypersensitivity to dimethyl sulfoxide or to porcine or bovine proteins, had severe baseline pulmonary disease requiring oxygen therapy prior to diagnosis of ARDS due to COVID-19 infection or had any end-stage organ disease.

Remestemcel-L is an investigational allogeneic cell product comprised of ex vivo-expanded MSC isolated from the bone marrow of adult healthy donors. The cells express mesenchymal lineage markers, including CD73, CD90, CD105 and CD166, and lack expression of hematopoietic cell surface antigens such as CD45 and CD31 [22] . They also express low levels of major histocompatibility complex (MHC) class I, are negative for major histocompatibility complex class II molecules, and are negative for costimulatory molecules CD40, CD80, and CD86.

MSC were harvested after five passages then harvested and formulated in a cryopreservation medium composed of Plasma-Lyte A, 10% dimethyl sulfoxide and human serum albumin solution. The cryopreserved remestemcel-L product for administration was stored in the vapor phase of liquid nitrogen (≤ -135°C) until use. Each dose was thawed, and reconstituted in Plasma-Lyte A immediately prior to administration. No manipulation occurred between thawing and administration.

Each patient received two intravenous remestemcel-L infusions at a dose of 2 x 10 6 cells/kg/infusion at an interval of 48-120 hours apart. This dose was chosen based on the safety and efficacy data in steroid refractory acute GVHD studies, in which this dose was given twice weekly for 4 weeks [13] [14] [15] . Cell viability ranged between 78-90%. Patients were pre-medicated with hydrocortisone and diphenhydramine at least 30 minutes prior to each remestemcel-L infusion as per institutional standard practice for cellular therapy infusions and manufacturer instructions. Patients were monitored for infusion-associated reactions by vital sign assessment 15 minutes prior to the infusion, every 15 minutes for the first hour after the start of the infusion, and at 120 minutes.

Clinical assessments included the baseline APACHE II score, daily Sequential Organ Failure Assessment (SOFA) score which represents a composite measure of organ failure [23] P:F ratio, days in the intensive care unit, days on mechanical ventilation and discharge disposition.

Laboratory assessments included hematology, chemistry, C-reactive protein (CRP) and ferritin, the latter two representing non-specific markers of inflammation. A pre-infusion baseline was established as the values on the day of intubation; or the following 24 hour period, not including the day of the first remestemcel-L infusion if data were missing. No imputations were made for data missing at days 0, 3 or 5. Chest radiography was performed at baseline but thereafter only as needed by standard of care protocols of the ICU.

The primary outcome was ICU mortality, and patients were followed at a minimum until death or discharge from the ICU. Secondary outcomes included proportion of patients who were extubated for greater than 48 hours, time to extubation after the initial remestemcel-L infusion, total duration of mechanical ventilation, proportion of patients discharged from the ICU and discharged from the hospital.

Given the nature of the eIND where the number of patients is small and a control group is lacking, standard descriptive statistics were used; categorical variables were reported as proportions with corresponding Clopper Pearson 95% confidence intervals for outcome variables. Continuous, non-normally distributed variables were reported as medians and interquartile ranges. Time to extubation was calculated using the Kaplan-Meier method. Changes in physiologic parameters were assessed for significance using the Friedman's test, with post-hoc analysis with Wilcoxon signed rank test (comparing day 0 to day 3 and day 5) of parameters that were significantly changed overall from pre-infusion baseline to day 5 post-infusion. The

Bonferroni correction method was applied to account for multiple comparisons.

Eleven patients were treated with remestemcel-L at the Mount Sinai Hospital per eIND treatment plan and were included in this analysis. All patients were screened within 24 hours of intubation and none demonstrated clinical improvement prior to treatment (Supplemental Table S2 ).

Individual patient characteristics are provided in Table S2 ). The most frequent comorbid conditions were: obesity (73%), diabetes mellitus (27%), hypertension (27%) and asthma (18%), and patients had a median baseline APACHE II score of 14 (IQR:12-16).

The median P:F ratio on day 0 was 120 (IQR: 103-205) mmHg. All had bilateral opacities on baseline chest radiograph, one patient had a post-intubation pneumothorax which subsequently improved with chest tube drainage.

All patients received vasopressor therapy (norepinephrine and/or vasopressin) before remestemcel-L administration (i.e. before day 0) (Supplemental Table S4 ). While the dose of vasopressors fluctuated, the number of patients on vasopressors decreased from six patients on day 0 to two patients on day 5 (Supplemental Table S5 ). In addition, the P:F ratio, which is a measure of hypoxemia improved from 120 on day 0 to 200 on day 5 and the SOFA score, which is a composite score of total organ failure, improved from 6.0 to 3.5 on day 0 to day 5, respectively (Supplemental Table S5 ). Of note, none of patients required renal replacement therapy during follow-up. All patients were treated with hydroxychloroquine, 45% received tocilizumab (an interleukin-6 receptor inhibitor; two (18%) received tocilizumab alone and three (27%) received tocilizumab and glucocorticoids (Supplemental Table S3 ). Seventy-three percent received glucocorticoids alone. Of note, administration of steroids was part of standard premedication when administering cellular therapy products and it was not given as COVID-19 related therapy. One patient did not receive steroids or tocilizumab, and none of the patients received anti-viral therapy due to lack of availability at such early time in the pandemic.

Clinical outcomes are shown in Figure 1A . All patients were followed minimally until death or ICU discharge, and the ICU mortality was 18% (95% CI; 2-52%). Over the period of observation, ten (91%, 95% CI; 59-100%) patients were extubated.

One patient (patient 7) was re-intubated due to worsening ARDS and possible pulmonary embolism. The patient was treated empirically with thrombolytic therapy and improved. The patient ultimately died at day 23 post-infusion from multiorgan failure. At the end of the study period, nine (82%, 95% CI; 48-97) patients were liberated from mechanical ventilation, nine (82%, 95% CI; 48-97) were discharged from the intensive care unit and eight (73%, 95% CI; 34-100) were discharged from the hospital. Two remained hospitalized in stable condition on the medical floor. The median time to extubation from first remestemcel-L infusion was ten days (IQR: 3-10 days). The median duration of mechanical ventilation was 12 days (IQR: 7-12 days, Table 2 ).

There was an improvement in oxygenation as assessed by the daily median P:F ratio (median difference +78 mmHg, p=0.002) from day 0 to day 3 (Supplemental Tables S4 and S6 , Supplementary Figure S1 ). CRP levels decreased from day 0 to day 5 (median value 219.2 to 36.5 mg/L, p=0.002, Figure 1B, Supplementary Tables S4 and S6 ).

There was no change in fever curve or white blood cell count (Supplemental Table S4 ). Ferritin levels and SOFA scores did not significantly change from day 0 to day 3 or 5. One patient (patient 2) had similar improvement in CRP following remestemcel-L infusion without exposure to tocilizumab or glucocorticoids (Supplemental Figure S2 ).

In addition to CRP and ferritin (Figure 1 and Supplemental Table S4 ), inflammatory cytokines such as IL-6, IL-1, IL-8 and TNF were also measured. Serum levels of IL-1 were within the normal range in all evaluated patients at all times and those for IL-6, IL-8 and TNF are summarized in Supplemental Table S7 and Figure S3 . However, due to the nature of the eIND, cytokine levels were not systematically measured. As a result, a statistical analysis could not be performed in order to draw a meaningful conclusion.

There were no infusion related adverse events. During the 28-days follow-up period, five patients had secondary infections and 2 patients died ( Table 2) . No adverse events were attributed to remestemcel-L infusions.

We report outcomes in a series of eleven critically ill patients with moderate to severe CARDS who were treated with remestemcel-L, an investigational, allogeneic, bone marrow-derived, off-the-shelf MSC product candidate. All but one patient were extubated shortly after remestemcel-L infusion and we observed an 82% rate of discharge from the ICU and a 28-day mortality rate of 18%. None of our patients required renal replacement therapy. We had an adequate period to observe that recovery was sustained in survivors. Although we did not comprehensively analyze markers of inflammation, we did observe a significant and sustained decrease in the inflammatory marker CRP coincident with clinical improvement. While we cannot conclude that these improvements were the direct result of treatment with remestemcel-L, our results are consistent with a previous report of recovery in 7 patients with mild to severe hypoxemia treated with a different MSC product in China, albeit none were mechanically ventilated at the time of treatment [19] .

The pathophysiology of ARDS is marked by increased inflammation leading to destruction of the alveolar capillary barrier, increased protein leakage and hyaline membrane formation in the alveoli with resultant oncotic pulmonary edema. Ex vivo-generated MSCs have demonstrated biologic efficacy in treating acute lung injury in pre-clinical studies [24, 25] . In animal models, bone marrow-derived MSCs were shown to migrate to the lungs where they remained for several weeks without engraftment during which time they released anti-inflammatory paracrine factors such as IL-1 receptor antagonist and prostaglandin E2, improve alveolar fluid clearance, and reduce bacterial overgrowth by releasing anti-microbial peptides [26] [27] [28] [29] [30] . These preclinical data are consistent with the observed decrease in CRP and TNF-alpha levels and decreased number of pro-inflammatory CD4+, CD8+ T cells and natural killer cells in the Chinese patients treated with MSCs for COVID-19 ARDS [19] .

The utility of MSCs in ARDS is an active area of inquiry. A Phase 1/2 trial of MSCs in moderate to severe ARDS in 30 participants randomized to a single infusion of 900 million cells or placebo was well tolerated with only a single adverse reaction [31] . While it was not powered to determine improvement in mortality, favorable trends were noted in the subgroup of patients with P:F ratio <150mmHg and a larger randomized controlled trial is underway (NCT04367077).

Similarly, a Phase 2a trial investigating a single infusion of 10 million MSCs/kg in patients with ARDS met its primary endpoint of safety but showed no improvement in mortality [18] .

However, this study was limited by low cell viability (ranging from 36-85%), and efficacy is being investigated in a Phase 2b trial (NCT03818854). It is possible that the efficacy of treatment with MSCs may vary among ARDS resulting from different etiologies. Further clinical and laboratory phenotyping of CARDS will be needed to understand how this novel disease differs from other causes of lung injury.

Remestemcel-L has been studied across a wide variety of demographic, exposure and disease states and there is similar safety in both pediatric and adult patients. Reports on more than 500 adult and pediatric patients with steroid refractory acute GVHD and adult patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) support a favorable safety profile for remestemcel-L [13] [14] [15] 32 ]. An updated systematic review and meta-analysis on the safety of mesenchymal stromal cells by Thompson et al. reported no significant safety signals which further supports the favorable safety profile of MSC administration [32] . Remestemcel-L infusions in this case series report were well tolerated. Thromboembolism is a serious complication in COVID-19 patients [33] . The single patient with a reported possible pulmonary embolism in this case series was an expected event given the high incidence of such events in COVID-19 ARDS patients generally. While a hypercoagulable state may theoretically occur in relation to MSC products that are either placental-derived, or adipose-derived, due to their high level of tissue factor expression, bone marrow-derived MSCs express much lower levels of tissue factor and have not been reported to portend risks for hypercoagulability [34] .

As a case series, our report has important limitations. First, the small size and lack of untreated control group prohibits any inference about efficacy. Second, our patients were selected based on severe lung injury who had been intubated for less than 72 hours and we excluded patients who had pre-existing severe lung disease, concomitant significant kidney and liver injury, or who had been intubated for more than 72 hours. As a result, we cannot generalize our results to patients who were at greater risk for death due to comorbid conditions or in the later phase of CARDS.

Third, our patients also received several concurrent therapies, namely hydroxychloroquine, tocilizumab and corticosteroids. Prior administration of tocilizumab or steroids may have facilitated the anti-inflammatory effect of remestemcel-L, although we note anecdotally that one patient recovered without receiving either agent. It is important to note that none of the patients in this series received remdesivir, a nucleotide analog that inhibits viral RNA polymerase, which has been shown to shorten the time to recovery in patients with COVID-19 [35] . Finally, clinical grade MSCs can be produced from different cell sources and under a variety of conditions. It is not yet clear how these different production methods affect biological activity in vivo. Thus, the outcomes we observed with remestemcel-L may not be reproduced with different MSCs.

Nonetheless, the results reported here demonstrate that administration of remestemcel-L was well tolerated and resulted in improved clinical outcomes including liberation from mechanical ventilation and discharge from the ICU and/or hospital. Although this eIND-case series of 11 critically ill adult patients was not structured to assess efficacy, it represented promising pilot data in support of a larger randomized controlled trial in COVID-19 ARDS (NCT 04371393).

During preparation of this manuscript, the randomized, controlled trial was halted by the trial's Data and Safety Monitoring Board (DSMB) after the third interim analysis because the primary endpoint of 30-day all-cause mortality would not be attained with the planned enrollment schedule. Evaluation of secondary endpoints and subgroup analysis are ongoing. Importantly, the DSMB noted no safety concerns.

Conception and design, Manuscript Writing, Final approval: SAWB, CIR, FG, SI, JL, KO Collection, assembly, analysis and interpretation of data: All authors

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Table 1 . B. C-Reactive Protein (CRP) Levels. Median and interquartile range of CRP were plotted according to time from remestemcel-L infusion.

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Clinical features of patients infected with 2019 novel coronavirus in

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Management of COVID-19 Respiratory Distress

ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease

of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome

COVID-19: consider cytokine storm syndromes and immunosuppression

Concise Review: Mesenchymal Stem (Stromal) Cells: Biology and Preclinical Evidence for Therapeutic Potential for Organ Dysfunction Following Trauma or Sepsis

Human mesenchymal stem cells modulate allogeneic immune cell responses

T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression

A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease

Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease

Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children

Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo

Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. The Lancet Respiratory medicine

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

Acute respiratory distress syndrome: the Berlin Definition

APACHE II: a severity of disease classification system

Remestemcel-L for the treatment of graft versus host disease

Serial evaluation of the SOFA score to predict outcome in critically ill patients

Prospects and progress in cell therapy for acute respiratory distress syndrome

Where next for cell-based therapy in ARDS

Epithelial interactions and local engraftment of lung-resident mesenchymal stem cells

Failure of bone marrow to reconstitute lung epithelium

Evidence that bone marrow cells do not contribute to the alveolar epithelium

Mesenchymal stem cells: a double-edged sword in regulating immune responses

Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37

Primary Analysis of a Phase 1/2 Study to Assess MultiStem® Cell Therapy, a Regenerative Advanced Therapy Medicinal Product (ATMP), in Acute Respiratory Distress Syndrome (MUST-ARDS)

Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis

Venous thromboembolism is linked to severity of disease in COVID-19 patients: A systematic literature review and exploratory meta-analysis

Editorial: Safety, Efficacy and Mechanisms of Action of Mesenchymal Stem Cell Therapies

Clinical trials for the prevention and treatment of COVID-19: current state of play

Table 1. Demographic and Pre-Treatment Disease Characteristics on ICU admission Table 2. Outcomes and Adverse Events Primary Outcome ICU mortality, n (%, 95% CI)

Secondary Outcomes Successful Extubation, n (%, 95% CI) 10 (91

Time to Successful Extubation

Duration of Mechanical Ventilation

Proportion Discharged from the ICU, n (%, 95% CI) 9

Proportion Discharged from the Hospital, n (%, 95% CI) 8 (73

Discharge Disposition, n (%, 95% CI) Home 5

Secondary Infections, n (%, 95% CI) 5

Remestemcel-L was provided by Mesoblast, Inc. The authors would like to thank the following